Alpha DNA Investment Management LLC Has $750,000 Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Alpha DNA Investment Management LLC decreased its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 31.0% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,092 shares of the biotechnology company’s stock after selling 940 shares during the quarter. Alpha DNA Investment Management LLC’s holdings in United Therapeutics were worth $750,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. UniSuper Management Pty Ltd increased its holdings in United Therapeutics by 133.3% during the first quarter. UniSuper Management Pty Ltd now owns 700 shares of the biotechnology company’s stock worth $161,000 after buying an additional 400 shares during the last quarter. Bayesian Capital Management LP acquired a new position in shares of United Therapeutics during the 1st quarter worth about $772,000. B. Riley Wealth Advisors Inc. bought a new stake in shares of United Therapeutics in the 1st quarter valued at about $219,000. California State Teachers Retirement System lifted its stake in United Therapeutics by 2.1% in the 1st quarter. California State Teachers Retirement System now owns 74,773 shares of the biotechnology company’s stock valued at $17,177,000 after purchasing an additional 1,525 shares during the last quarter. Finally, Tidal Investments LLC grew its holdings in United Therapeutics by 2.1% during the first quarter. Tidal Investments LLC now owns 8,269 shares of the biotechnology company’s stock worth $1,945,000 after purchasing an additional 167 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Ratings Changes

UTHR has been the topic of several research analyst reports. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Argus increased their price target on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. HC Wainwright lifted their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. The Goldman Sachs Group upped their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a report on Friday, November 1st. Finally, Wells Fargo & Company raised their target price on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 20th. One research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $370.86.

Insider Buying and Selling

In related news, CEO Martine A. Rothblatt sold 269 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $348.41, for a total transaction of $93,722.29. Following the completion of the sale, the chief executive officer now directly owns 130 shares in the company, valued at $45,293.30. This represents a 67.42 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Michael Benkowitz sold 15,000 shares of the business’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $401.44, for a total value of $6,021,600.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $1,034,510.88. The trade was a 85.34 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 117,496 shares of company stock valued at $43,765,042 over the last quarter. 11.90% of the stock is owned by company insiders.

United Therapeutics Stock Up 1.5 %

Shares of NASDAQ:UTHR opened at $372.89 on Friday. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $417.82. The company’s 50 day moving average price is $365.06 and its two-hundred day moving average price is $331.82. The firm has a market cap of $16.65 billion, a PE ratio of 16.38, a PEG ratio of 1.07 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating the consensus estimate of $6.16 by $0.23. The firm had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $5.38 EPS. On average, research analysts expect that United Therapeutics Co. will post 25.22 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.